Known targets — ChEMBL curated mechanism
COXFA4COXFA4L2MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3
The experimentally established mechanism targets of Me-344. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 9/20 | 0.36 |
| ▸ | ESR1 | P03372 | 8/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Me-344 SCHEMBL2713213 | 1.00 | ESR2 (0.36) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| Me-344 SCHEMBL29370582 | 1.00 | ESR2 (0.36) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| Me-344 SCHEMBL30276333 | 1.00 | ESR2 (0.36) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| Me-344 SCHEMBL17965959 | 1.00 | ESR2 (0.36) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| Me-344 SCHEMBL15312098 | 1.00 | ESR2 (0.36) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| Me-344 SCHEMBL30362759 | 1.00 | ESR2 (0.36) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| SCHEMBL15965356 | 0.96 | ALOX15 (0.41) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| SCHEMBL17916795 | 0.96 | ALOX15 (0.41) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| SCHEMBL15312298 | 0.92 | ALOX15 (0.44) | ESR2ESR1PTGS1ALOX15ALOX12 | |
| SCHEMBL301907 | 0.92 | ALOX15 (0.44) | ESR2ESR1PTGS1ALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12329739-B2 | Isoflavonoid compounds and methods for the treatment of cancer | Aardvark Therapeutic, Inc. (US) | 2025-06-17 | — | — | US | claimed |
| US-12318364-B2 | Isoflavonoid compositions and methods for the treatment of cancer | Aardvark Therapeutics, Inc. (US) | 2025-06-03 | — | — | US | claimed |
| WO-2024137472-A2 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2024-06-27 | — | — | WO | claimed |
| US-20240165073-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2024-05-23 | — | — | US | claimed |
| US-11723893-B2 | Isoflavonoid compositions and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2023-08-15 | — | — | US | claimed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | claimed |
| CN-116113414-A | Combination therapy | 梅制药公司 | 2023-05-12 | — | — | CN | claimed |
| EP-4164632-A1 | COMBINATION THERAPIES | MEI Pharma, Inc. (US) | 2023-04-19 | — | — | EP | claimed |
| US-11583514-B2 | Isoflavonoid compounds and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2023-02-21 | — | — | US | claimed |
| EP-4132500-A1 | COMBINATORY TREATMENT FOR LYMPHOMA | Université Paris Cité (FR) | 2023-02-15 | — | — | EP | claimed |
| WO-2021252776-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2021-12-16 | — | — | WO | claimed |
| EP-3892267-A1 | COMBINATORY TREATMENT FOR LYMPHOMA | Université de Paris (FR) | 2021-10-13 | — | — | EP | claimed |
| US-20190142790-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. | 2019-05-16 | — | — | US | claimed |
| US-12414934-B2 | Combination therapies | Aardvark Therapeutics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| US-12329739-B2 | Isoflavonoid compounds and methods for the treatment of cancer | Aardvark Therapeutic, Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| US-12318364-B2 | Isoflavonoid compositions and methods for the treatment of cancer | Aardvark Therapeutics, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20130273177-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130273177-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2012061413-A2 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061409-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414934-B2 | Combination therapies | PCK2, PDK1, PCK1 | ESR2 1403/4885ESR1 2467/4885PTGS1 1926/4885 |
| US-11723893-B2 | Isoflavonoid compositions and methods for the treatment of cancer | BAX, CASP3, SI | ESR2 154/4885ESR1 176/4885PTGS1 1103/4885 |
| US-20240165073-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, SI | ESR2 154/4885ESR1 176/4885PTGS1 1103/4885 |
| US-20130273177-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, SI | ESR2 154/4885ESR1 176/4885PTGS1 1103/4885 |
| US-20230233519-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL2L2 | ESR2 2187/4885ESR1 3784/4885PTGS1 1212/4885 |
| US-12318364-B2 | Isoflavonoid compositions and methods for the treatment of cancer | BAX, CASP3, SI | ESR2 154/4885ESR1 176/4885PTGS1 1103/4885 |
| US-20190142790-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | ESR2 22/4885ESR1 57/4885PTGS1 326/4885 |
| US-11583514-B2 | Isoflavonoid compounds and methods for the treatment of cancer | BAX, CASP3, API5 | ESR2 22/4885ESR1 57/4885PTGS1 326/4885 |
| US-12329739-B2 | Isoflavonoid compounds and methods for the treatment of cancer | BAX, CASP3, API5 | ESR2 22/4885ESR1 57/4885PTGS1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.